D441 OBJECTIVE ASSESSMENT -
WGU PHARMACOLOGY OA -
(2026) ACTUAL QUESTIONS &
LATEST MOCK PRACTICE SET
170 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
D441 OBJECTIVE ASSESSMENT - WGU PHARMACOLOGY OA - (2026) ACTUAL QUESTIONS & STUDY
GUIDE | GUARANTEE PASS. It contains 170 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 170 Questions
Foundations - Application - D441 Objective Assessment WGU Pharmacology OA 2026 Actual & Study
Guide Guarantee PASS D441 Objective Assessment WGU Pharmacology OA 2026 Actual & Study Guide
Guarantee PASS University
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Started 1-43 Prescribed, Mechanism, Appropriate, Explains, Chronic
Prescribed 44-86 Develops, Likely, Started, Therapy, Kidney
Appropriate 87-129 Prescribed, Mechanism, Describes, Started, Likely
Mechanism 130-170 Started, Prescribed, Appropriate, Explains, Medication
TOTAL 170 All questions include answers and detailed rationales
,Section A - Started
Q1.
A patient on chronic warfarin therapy presents with an INR of 5.2 and minor bleeding.
Which management strategy is most appropriate?
A. Hold warfarin and administer oral vitamin B. Administer fresh frozen plasma
K 1-2 mg immediately
C. Give intravenous vitamin K 10 mg slow D. Continue warfarin and monitor INR in 24
push hours
Correct: A - Hold warfarin and administer oral vitamin K 1-2 mg
Rationale:In warfarin overdose with INR >4 and minor bleeding, guidelines recommend
withholding warfarin and giving low-dose oral or intravenous vitamin K (1-2 mg). FFP is
reserved for life-threatening bleeding, IV 10 mg would cause overcorrection, and continuing
warfarin is unsafe.
Q2.
A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) needs an
antihyperglycemic agent. Which medication is contraindicated in this renal function?
A. Metformin B. Liraglutide
C. Empagliflozin D. Insulin glargine
Correct: A - Metformin
Rationale:Metformin is contraindicated when eGFR <30 mL/min and should be reduced
when eGFR 30-45. Liraglutide and empagliflozin can be used with reduced eGFR
(empagliflozin down to 30), and insulin is generally safe with dose adjustment.
Q3.
Which pharmacokinetic parameter is most altered in a patient with decompensated
cirrhosis, and how does it affect drug dosing?
A. Increased renal clearance; require higher B. Decreased first-pass metabolism; require
doses lower oral doses
C. Increased plasma protein binding; require D. Decreased volume of distribution; require
higher doses loading dose reduction
Correct: B - Decreased first-pass metabolism; require lower oral doses
Page 3
, Section A - Started
Rationale: Cirrhosis reduces hepatic enzyme activity and portal blood flow, decreasing
first-pass metabolism, so oral bioavailability increases and lower doses are needed. Renal
clearance is not increased, protein binding usually decreases (due to hypoalbuminemia), and
volume of distribution may increase.
Q4.
A patient on a stable dose of digoxin is started on clarithromycin for pneumonia. What is
the most likely interaction and appropriate management?
A. Decreased digoxin absorption; increase B. Increased digoxin toxicity; monitor levels
digoxin dose and reduce dose
C. Antagonistic effect on heart rate; no D. Increased renal excretion of digoxin;
change needed monitor renal function
Correct: B - Increased digoxin toxicity; monitor levels and reduce dose
Rationale:Clarithromycin inhibits P-glycoprotein, decreasing digoxin renal tubular secretion
and increasing its serum levels, leading to toxicity. Management includes monitoring digoxin
levels and reducing the dose. Other options are incorrect mechanisms.
Q5.
Which statement accurately compares the mechanism of action of bisphosphonates and
denosumab in osteoporosis treatment?
A. Both inhibit osteoclast activity, but B. Bisphosphonates increase bone
bisphosphonates induce apoptosis and formation, denosumab inhibits bone
denosumab inhibits RANKL resorption
C. Both stimulate osteoblast activity via D. Bisphosphonates act on osteoclasts,
different receptors denosumab acts on osteoblasts
Correct: A - Both inhibit osteoclast activity, but bisphosphonates induce apoptosis and
denosumab inhibits RANKL
Rationale:Bisphosphonates are taken up by osteoclasts and induce apoptosis, while
denosumab is a monoclonal antibody against RANKL, preventing osteoclast maturation. Both
ultimately reduce resorption, but the mechanisms differ as described.
Q6.
A patient with an opioid use disorder is started on buprenorphine/naloxone. What is the
rationale for including naloxone in the formulation?
A. To enhance the analgesic effect of B. To prevent diversion and intravenous
buprenorphine abuse
Page 4
WGU PHARMACOLOGY OA -
(2026) ACTUAL QUESTIONS &
LATEST MOCK PRACTICE SET
170 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
D441 OBJECTIVE ASSESSMENT - WGU PHARMACOLOGY OA - (2026) ACTUAL QUESTIONS & STUDY
GUIDE | GUARANTEE PASS. It contains 170 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 170 Questions
Foundations - Application - D441 Objective Assessment WGU Pharmacology OA 2026 Actual & Study
Guide Guarantee PASS D441 Objective Assessment WGU Pharmacology OA 2026 Actual & Study Guide
Guarantee PASS University
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Started 1-43 Prescribed, Mechanism, Appropriate, Explains, Chronic
Prescribed 44-86 Develops, Likely, Started, Therapy, Kidney
Appropriate 87-129 Prescribed, Mechanism, Describes, Started, Likely
Mechanism 130-170 Started, Prescribed, Appropriate, Explains, Medication
TOTAL 170 All questions include answers and detailed rationales
,Section A - Started
Q1.
A patient on chronic warfarin therapy presents with an INR of 5.2 and minor bleeding.
Which management strategy is most appropriate?
A. Hold warfarin and administer oral vitamin B. Administer fresh frozen plasma
K 1-2 mg immediately
C. Give intravenous vitamin K 10 mg slow D. Continue warfarin and monitor INR in 24
push hours
Correct: A - Hold warfarin and administer oral vitamin K 1-2 mg
Rationale:In warfarin overdose with INR >4 and minor bleeding, guidelines recommend
withholding warfarin and giving low-dose oral or intravenous vitamin K (1-2 mg). FFP is
reserved for life-threatening bleeding, IV 10 mg would cause overcorrection, and continuing
warfarin is unsafe.
Q2.
A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) needs an
antihyperglycemic agent. Which medication is contraindicated in this renal function?
A. Metformin B. Liraglutide
C. Empagliflozin D. Insulin glargine
Correct: A - Metformin
Rationale:Metformin is contraindicated when eGFR <30 mL/min and should be reduced
when eGFR 30-45. Liraglutide and empagliflozin can be used with reduced eGFR
(empagliflozin down to 30), and insulin is generally safe with dose adjustment.
Q3.
Which pharmacokinetic parameter is most altered in a patient with decompensated
cirrhosis, and how does it affect drug dosing?
A. Increased renal clearance; require higher B. Decreased first-pass metabolism; require
doses lower oral doses
C. Increased plasma protein binding; require D. Decreased volume of distribution; require
higher doses loading dose reduction
Correct: B - Decreased first-pass metabolism; require lower oral doses
Page 3
, Section A - Started
Rationale: Cirrhosis reduces hepatic enzyme activity and portal blood flow, decreasing
first-pass metabolism, so oral bioavailability increases and lower doses are needed. Renal
clearance is not increased, protein binding usually decreases (due to hypoalbuminemia), and
volume of distribution may increase.
Q4.
A patient on a stable dose of digoxin is started on clarithromycin for pneumonia. What is
the most likely interaction and appropriate management?
A. Decreased digoxin absorption; increase B. Increased digoxin toxicity; monitor levels
digoxin dose and reduce dose
C. Antagonistic effect on heart rate; no D. Increased renal excretion of digoxin;
change needed monitor renal function
Correct: B - Increased digoxin toxicity; monitor levels and reduce dose
Rationale:Clarithromycin inhibits P-glycoprotein, decreasing digoxin renal tubular secretion
and increasing its serum levels, leading to toxicity. Management includes monitoring digoxin
levels and reducing the dose. Other options are incorrect mechanisms.
Q5.
Which statement accurately compares the mechanism of action of bisphosphonates and
denosumab in osteoporosis treatment?
A. Both inhibit osteoclast activity, but B. Bisphosphonates increase bone
bisphosphonates induce apoptosis and formation, denosumab inhibits bone
denosumab inhibits RANKL resorption
C. Both stimulate osteoblast activity via D. Bisphosphonates act on osteoclasts,
different receptors denosumab acts on osteoblasts
Correct: A - Both inhibit osteoclast activity, but bisphosphonates induce apoptosis and
denosumab inhibits RANKL
Rationale:Bisphosphonates are taken up by osteoclasts and induce apoptosis, while
denosumab is a monoclonal antibody against RANKL, preventing osteoclast maturation. Both
ultimately reduce resorption, but the mechanisms differ as described.
Q6.
A patient with an opioid use disorder is started on buprenorphine/naloxone. What is the
rationale for including naloxone in the formulation?
A. To enhance the analgesic effect of B. To prevent diversion and intravenous
buprenorphine abuse
Page 4
